Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
AstraZeneca Stock Falls
AstraZeneca in AI Collaboration With Immunai to Inform Cancer Drug Trials
(Reuters) - AstraZeneca will pay $18 million to biotechnology firm Immunai Inc to use the New York-based firm's AI model of the immune system to make certain cancer drug trials more efficient, the latter said on Thursday.
AstraZeneca Stock Falls After Disappointing Results in Breast Cancer Drug Trial
A cancer drug being developed by AstraZeneca failed to "achieve statistical significance" in helping patients live longer than with chemotherapy in a phase 3 trial, the drugmaker said Monday.
Latest Trial Setback For AstraZeneca's Dato-DXd, The Drug Fails To Extend Lives Of Pretreated Breast Cancer Patients
AstraZeneca released results from the TROPION-Breast01 Phase 3 trial of datopotamab deruxtecan, showing no statistically significant improvement in overall survival. The trial met its progression-free survival endpoint,
AstraZeneca's experimental drug disappoints in breast cancer survival trial
AstraZeneca said on Monday its experimental precision drug developed with Japan's Daiichi Sankyo did not significantly improve overall survival for patients with a type of breast cancer in a late-stage trial.
AstraZeneca drug fails to extend lives of breast cancer patients
A new AstraZeneca drug has failed to extend significantly the lives of breast cancer patients in a blow to the company’s ambitions to hit an $80bn revenue target by 2030. Datopotamab deruxtecan (Dato-DXd) is a new form of cancer treatment,
AstraZeneca Stock Dips On Surprise Miss For Gilead-Rivaling Cancer Drug
AstraZeneca stock slumped Monday after its Daiichi Sankyo-partnered drug missed its mark in a study of patients with breast cancer.
AstraZeneca's experimental cancer drug shows no significant improvement in overall survival
AstraZeneca said on Monday its experimental precision drug developed with Daiichi Sankyo did not significantly improve overall survival for patients with a type of breast cancer in a late-stage trial.
12h
on MSN
AstraZeneca (AZN): A Strong Buy as FDA Approves Key Cancer Treatments and Revenue Surges
We recently published a list of 10 Best Major Stocks to Invest In According to Analysts. In this article, we are going to ...
Yicai Global
18h
AstraZeneca Doubles Down on Chronic, Rare Disease Innovation in China
(Yicai) Sept. 30 -- AstraZeneca will strengthen its commitment to researching chronic and rare diseases in China, driving ...
FierceBiotech
7d
AstraZeneca, Daiichi's Trodelvy rival fails to improve overall survival in breast cancer trial
AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate (ADC) has again failed to improve overall survival ...
14h
on MSN
Is AstraZeneca PLC (NASDAQ:AZN) The Top Global Stock To Buy Now?
We recently made a list of the 10 Best Global Stocks To Buy Now. In this piece, we will look at where AstraZeneca PLC (NASDAQ ...
中国日报网
1d
AstraZeneca announces plans for new innovations for China
United Kingdom-based biopharmaceutical giant AstraZeneca will add 10 to 15 new projects to the company's research and ...
MM&M
3d
AstraZeneca’s ‘What science can do’ campaign highlights company’s scientific achievements
In several short films directed by Reed Morano, the “What science can do” campaign features stories from a cancer patient and an asthma patient.
The Motley Fool UK
4d
As AstraZeneca’s share price drops 13% should I buy on the dip?
AstraZeneca
’s share price has fallen following unfavourable results for one of its new drugs, but others look good, and ...
cnbctv18
18h
AstraZeneca aims to accelerate introduction of innovative medicines in India
Dr Sanjeev Panchal, Country President and MD, AstraZeneca India, stated company's mission to bring innovative medicine faster ...
FierceBiotech
4d
AstraZeneca extends AI immuno-oncology R&D pact with Immunai
AstraZeneca is extending its work with Immunai through a multiyear collaboration that aims to implement its ...
MarketWatch
11h
AstraZeneca outperforms market despite losses on the day
Shares of
AstraZeneca
PLC AZN inched down 0.57% to £115.88 Monday, on what proved to be an all-around grim trading session ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
China
India
Artificial intelligence
Trade
United States
Feedback